The FDA approved a sublingual formulation of cyclobenzaprine (Tonmya, Tonix Pharmaceuticals) for the treatment of fibromyalgia. The approval allows Tonix to move forward and market the first-in-class, nonopioid, once-daily bedtime analgesic with a unique sublingual formulation aimed at providing rapid absorption into the bloodstream for patients with fibromyalgia.
Tonmya is the first drug approved for the condition in more than 15 years.
“The FDA approval of Tonmya as a first-line